Does the media prefer BMY or AMGN?

In the previous week, Bristol Myers Squibb and Bristol Myers Squibb both had 28 articles in the media. Bristol Myers Squibb's average media sentiment score of 0.88 beat Amgen's score of 0.73 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 15 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 14 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media favor BMY or EXEL?

In the previous week, Bristol Myers Squibb had 25 more articles in the media than Exelixis. MarketBeat recorded 28 mentions for Bristol Myers Squibb and 3 mentions for Exelixis. Exelixis' average media sentiment score of 0.91 beat Bristol Myers Squibb's score of 0.88 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 15 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GILD or BMY?

In the previous week, Bristol Myers Squibb had 14 more articles in the media than Gilead Sciences. MarketBeat recorded 28 mentions for Bristol Myers Squibb and 14 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.96 beat Bristol Myers Squibb's score of 0.88 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bristol Myers Squibb 15 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BMY or VRTX?

In the previous week, Bristol Myers Squibb had 11 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 28 mentions for Bristol Myers Squibb and 17 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.93 beat Bristol Myers Squibb's score of 0.88 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 15 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BMY or ABBV?

In the previous week, AbbVie had 12 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 40 mentions for AbbVie and 28 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 0.88 beat AbbVie's score of 0.75 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 15 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 18 Very Positive mention(s) 11 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Bristol Myers Squibb (BMY) Competitors

$62.90 -0.98 (-1.53%)

Closing price 03:59 PM Eastern

Extended Trading

$63.16 +0.26 (+0.42%)

As of 05:48 PM Eastern

Compare

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

Should you buy Bristol Myers Squibb stock or one of its competitors? Bristol Myers Squibb's main competitors and comparable companies include Amgen (AMGN), Exelixis (EXEL), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and AbbVie (ABBV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Bristol Myers Squibb compare to Amgen?

Bristol Myers Squibb (NYSE:BMY) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

In the previous week, Bristol Myers Squibb and Bristol Myers Squibb both had 28 articles in the media. Bristol Myers Squibb's average media sentiment score of 0.88 beat Amgen's score of 0.73 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	15 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	14 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bristol Myers Squibb presently has a consensus target price of $67.06, suggesting a potential upside of 6.61%. Amgen has a consensus target price of $385.25, suggesting a potential downside of 9.06%. Given Bristol Myers Squibb's stronger consensus rating and higher probable upside, equities analysts plainly believe Bristol Myers Squibb is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.62
Amgen	3 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.33

Amgen has a net margin of 22.95% compared to Bristol Myers Squibb's net margin of 18.87%. Amgen's return on equity of 124.14% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Amgen	22.95%	124.14%	13.18%

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.0%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.4%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Amgen pays out 62.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has raised its dividend for 17 consecutive years and Amgen has raised its dividend for 14 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Amgen has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Amgen has lower revenue, but higher earnings than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.67	$7.05B	$4.54	13.85
Amgen	$36.75B	6.23	$7.71B	$16.09	26.33

Summary

Bristol Myers Squibb beats Amgen on 10 of the 19 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Exelixis?

Bristol Myers Squibb (NYSE:BMY) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Bristol Myers Squibb presently has a consensus price target of $67.06, suggesting a potential upside of 6.61%. Exelixis has a consensus price target of $50.29, suggesting a potential downside of 14.26%. Given Bristol Myers Squibb's stronger consensus rating and higher possible upside, analysts clearly believe Bristol Myers Squibb is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.62
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Bristol Myers Squibb has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Bristol Myers Squibb has higher revenue and earnings than Exelixis. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.67	$7.05B	$4.54	13.85
Exelixis	$2.32B	6.26	$782.57M	$3.18	18.44

Exelixis has a net margin of 35.33% compared to Bristol Myers Squibb's net margin of 18.87%. Bristol Myers Squibb's return on equity of 66.90% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Exelixis	35.33%	42.17%	31.76%

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 2.6% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Bristol Myers Squibb had 25 more articles in the media than Exelixis. MarketBeat recorded 28 mentions for Bristol Myers Squibb and 3 mentions for Exelixis. Exelixis' average media sentiment score of 0.91 beat Bristol Myers Squibb's score of 0.88 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	15 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bristol Myers Squibb beats Exelixis on 9 of the 17 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Bristol Myers Squibb has a net margin of 18.87% compared to Gilead Sciences' net margin of -10.64%. Bristol Myers Squibb's return on equity of 66.90% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Bristol Myers Squibb	18.87%	66.90%	14.74%

Gilead Sciences presently has a consensus target price of $158.78, indicating a potential upside of 4.96%. Bristol Myers Squibb has a consensus target price of $67.06, indicating a potential upside of 6.61%. Given Bristol Myers Squibb's higher possible upside, analysts clearly believe Bristol Myers Squibb is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.86
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.62

In the previous week, Bristol Myers Squibb had 14 more articles in the media than Gilead Sciences. MarketBeat recorded 28 mentions for Bristol Myers Squibb and 14 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.96 beat Bristol Myers Squibb's score of 0.88 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	15 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences has higher earnings, but lower revenue than Bristol Myers Squibb. Gilead Sciences is trading at a lower price-to-earnings ratio than Bristol Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	6.37	$8.51B	-$2.67	N/A
Bristol Myers Squibb	$48.19B	2.67	$7.05B	$4.54	13.85

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.2%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.0%. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 10 consecutive years and Bristol Myers Squibb has raised its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Bristol Myers Squibb beats Gilead Sciences on 11 of the 20 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Bristol Myers Squibb (NYSE:BMY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bristol Myers Squibb currently has a consensus price target of $67.06, indicating a potential upside of 6.61%. Vertex Pharmaceuticals has a consensus price target of $575.13, indicating a potential upside of 9.19%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.62
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96

Bristol Myers Squibb has higher revenue and earnings than Vertex Pharmaceuticals. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.67	$7.05B	$4.54	13.85
Vertex Pharmaceuticals	$12.00B	11.14	$3.95B	$17.18	30.66

Bristol Myers Squibb has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Bristol Myers Squibb's net margin of 18.87%. Bristol Myers Squibb's return on equity of 66.90% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

In the previous week, Bristol Myers Squibb had 11 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 28 mentions for Bristol Myers Squibb and 17 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.93 beat Bristol Myers Squibb's score of 0.88 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	15 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vertex Pharmaceuticals beats Bristol Myers Squibb on 12 of the 17 factors compared between the two stocks.

How does Bristol Myers Squibb compare to AbbVie?

Bristol Myers Squibb (NYSE:BMY) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Bristol Myers Squibb has higher earnings, but lower revenue than AbbVie. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.67	$7.05B	$4.54	13.85
AbbVie	$64.39B	7.23	$4.23B	$3.54	74.45

Bristol Myers Squibb has a net margin of 18.87% compared to AbbVie's net margin of 9.80%. Bristol Myers Squibb's return on equity of 66.90% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
AbbVie	9.80%	-422.07%	14.34%

In the previous week, AbbVie had 12 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 40 mentions for AbbVie and 28 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 0.88 beat AbbVie's score of 0.75 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	15 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	18 Very Positive mention(s)	11 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Bristol Myers Squibb has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Bristol Myers Squibb presently has a consensus price target of $67.06, indicating a potential upside of 6.61%. AbbVie has a consensus price target of $272.66, indicating a potential upside of 3.46%. Given Bristol Myers Squibb's higher possible upside, analysts clearly believe Bristol Myers Squibb is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.62
AbbVie	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.0%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb has increased its dividend for 17 consecutive years and AbbVie has increased its dividend for 53 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Bristol Myers Squibb beats AbbVie on 10 of the 19 factors compared between the two stocks.

Get Bristol Myers Squibb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMY vs. The Competition

Export

Metric	Bristol Myers Squibb	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$128.49B	$12.55B	$7.26B	$22.74B
Dividend Yield	4.01%	2.62%	2.52%	3.68%
P/E Ratio	13.85	789.85	274.72	27.68
Price / Sales	2.67	752.55	606.70	20.20
Price / Cash	7.73	15.22	28.02	19.27
Price / Book	6.92	10.59	10.49	4.64
Net Income	$7.05B	$2.83B	$3.50B	$1.07B
7 Day Performance	1.11%	-2.62%	-3.03%	-2.80%
1 Month Performance	-5.58%	-1.41%	-4.16%	-5.85%
1 Year Performance	42.57%	-0.33%	13.20%	5.75%

Bristol Myers Squibb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMY Bristol Myers Squibb	4.6201 of 5 stars	$62.90 -1.5%	$67.06 +6.6%	+44.7%	$128.49B	$48.19B	13.85	32,500
AMGN Amgen	3.4127 of 5 stars	$406.04 0.0%	$383.46 -5.6%	+53.2%	$221.79B	$36.75B	25.24	31,500	Analyst Forecast
EXEL Exelixis	3.1608 of 5 stars	$57.95 +2.2%	$50.29 -13.2%	+49.5%	$14.41B	$2.32B	18.22	1,077
GILD Gilead Sciences	4.0474 of 5 stars	$149.69 -1.1%	$158.78 +6.1%	+35.8%	$189.30B	$29.44B	N/A	17,000
VRTX Vertex Pharmaceuticals	3.668 of 5 stars	$522.38 +1.2%	$573.83 +9.8%	+36.8%	$130.71B	$12.00B	30.41	6,400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BMY) was last updated on 9/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Does the media prefer BMY or AMGN?

Do institutionals and insiders hold more shares of BMY or AMGN?

Do analysts prefer BMY or AMGN?

Is BMY or AMGN more profitable?

Is BMY or AMGN a better dividend stock?

Which has more volatility & risk, BMY or AMGN?

Which has higher valuation and earnings, BMY or AMGN?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Do analysts recommend BMY or EXEL?

Which has more risk & volatility, BMY or EXEL?

Which has preferable earnings and valuation, BMY or EXEL?

Is BMY or EXEL more profitable?

Do institutionals & insiders have more ownership in BMY or EXEL?

Does the media favor BMY or EXEL?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Is GILD or BMY more profitable?

Do analysts prefer GILD or BMY?

Does the media prefer GILD or BMY?

Which has better earnings and valuation, GILD or BMY?

Is GILD or BMY a better dividend stock?

Which has more risk & volatility, GILD or BMY?

Do institutionals & insiders have more ownership in GILD or BMY?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Do insiders & institutionals hold more shares of BMY or VRTX?

Do analysts rate BMY or VRTX?

Which has better earnings and valuation, BMY or VRTX?

Which has more volatility & risk, BMY or VRTX?

Is BMY or VRTX more profitable?

Does the media prefer BMY or VRTX?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Which has higher earnings and valuation, BMY or ABBV?

Is BMY or ABBV more profitable?

Does the media prefer BMY or ABBV?

Which has more risk & volatility, BMY or ABBV?

Do analysts recommend BMY or ABBV?

Do institutionals & insiders have more ownership in BMY or ABBV?

Is BMY or ABBV a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools